Clinical trials
catalyst calendar across sponsors →Studies where BLLN is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 observational
Held by 11 tracked-famous managers (BAILLIE GIFFORD & CO, MILLENNIUM MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, Verition Fund Management LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, +6 more) · FINRA short interest 3.4 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 34 sells · government filings 180d: none disclosed
| Study | Phase | Status | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach to Non-invasive Fetal Risk AssessmentNCT07643896observationalConcordance | — | Recruiting | Pregnant Individuals, Aneuploidy, Down Syndrome (Trisomy 21), 22q11.2 Deletion Syndrome, Trisomy 13, Trisomy 18, Sex Chromosome Abnormalities | 1,000 | Dec 2027 | ≤ 499 d | 2026-06-12 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19